围产期心肌病的诊疗现状和研究进展  

Diagnosis,treatment,and research progress of peripartum cardiomyopathy

作　　者：王清鹏 余文军 刘金平 WANG Qingpeng;YU Wenjun;LIU Jinping(Department of Cardiovascular Surgery,Zhongnan Hospital of Wuhan University,Wuhan,430071,China;Hubei Province Engineering Research Center of Minimally Invasive Cardiovascular Surgery;Wuhan Clinical Research Center for Minimally Invasive Treatment of Structural Heart Disease)

机构地区：[1]武汉大学中南医院心血管外科,武汉430071 [2]心脏大血管外科微创诊疗湖北省工程研究中心 [3]武汉市结构性心脏病微创诊疗临床医学研究中心

出　　处：《临床心血管病杂志》2025年第3期188-195,共8页Journal of Clinical Cardiology

基　　金：国家自然科学基金项目(No:82370278);武汉大学中南医院博士(后)计划(No:ZNYB2021010);武汉大学中南医院优秀青年和中青年人才培养计划(No:ZNYQ2022002)。

摘　　要：围产期心肌病(peripartum cardiomyopathy,PPCM)是在妊娠晚期和分娩后6个月内发生的心肌功能障碍。其发病早期不易诊断,受多种危险因素的影响,病理生理机制复杂,预后差异大,近年来逐渐引起关注。本文将详细综述PPCM在临床表现、诊断、治疗、预后、发病机制和研究现状等方面的进展。Peripartum cardiomyopathy(PPCM)is a myocardial dysfunction that occurs in late pregnancy or within 6 months after delivery.The early diagnosis of PPCM is difficult,and the disease is influenced by multiple risk factors,with a complex pathophysiological mechanism and significant variability in prognosis.In recent years,it has gradually attracted attention.This article will comprehensively review the progress of PPCM in clinical manifestations,diagnosis,treatment,prognosis,pathogenesis,and research status.

关 键 词：围产期心肌病 心力衰竭 血管生成 氧化应激 

分 类 号：R542.2[医药卫生—心血管疾病]